inflammatory%20bowel%20disease
INFLAMMATORY BOWEL DISEASE
Inflammatory bowel disease consists of ulcerative colitis and Crohn's disease.
Ulcerative colitis is a diffuse mucosal inflammation limited to the colon while Crohn's disease is a patchy, transmural inflammation that occurs in any part of the gastrointestinal tract.
The ileum and colon are the most frequently affected sites.

Introduction

  • Consists of ulcerative colitis (UC) and Crohn’s disease (CD)
    • UC: Diffuse mucosal inflammation limited to the colon
    • CD: Patchy, transmural inflammation that can occur in any part of the GI tract
      • Ileum and colon are the most frequently affected sites

Signs and Symptoms

General Symptoms

Depend on the segment of the intestinal tract involved

  • Chronic diarrhea or constipation
  • Abdominal pain and cramps
  • Blood in stool
  • Pain with bowel movement
  • Urgency in bowel movement
  • Tenesmus
  • Reduced appetite
  • Weight loss
  • Fever
  • Fatigue
  • Growth retardation
  • Primary amenorrhea
  • Night sweats

Clinical Features

Ulcerative Colitis (UC)

  • Cardinal symptoms: Bloody diarrhea, frequent, small volume
  • Associated symptoms: Colicky abdominal pain, tenesmus, urgency

Crohn's Disease (CD)

  • Chronic diarrhea, abdominal pain, weight loss
  • Abdominal mass, perianal lesions, stomatitis, fissures and fistulas
  • Malaise, fever, anorexia are more common with CD than UC

Risk Factors

Risk Factors

  • Smoking is a risk factor for CD but has a protective factor for UC through unknown mechanism
  • Age - most people are diagnosed between 15 and 35 years
  • UC is more common in men while CD is more frequent in women
  • Family history
  • Recent episodes of infectious gastroenteritis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
23 Nov 2017
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
12 Nov 2017
Tocilizumab may improve skin score and forced vital capacity stabilization in patients with systemic sclerosis, while potentially increasing the risk of serious infections, according to the open-label data of the faSScinate* trial.
Audrey Abella, 21 Nov 2017
The infliximab (IFX) biosimilar SB2, whether administered long-term or switched from IFX, had comparable efficacy and safety as IFX for rheumatoid arthritis (RA), a study has found.
30 Nov 2017
There are significant associations between comorbidities and hand osteoarthritis (OA) disease burden, a recent study has found.